Publications: 2003

Ayyoub, M., Rimoldi, D., Guillaume, P., Romero, P., Cerottini, J.-C., Valmori, D. and Speiser, D. 2003. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients. Cancer Res. 63:5601-5606.

Ayyoub, M., Zippelius, A., Pittet, M.J., Rimoldi, D., Valmori, D., Cerottini, J.-C., Romero, P., Lejeune, F., Liénard, D. and Speiser, D.E. 2003. Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1. Clin. Cancer Res. 9:669-677.

Capone, M., Cantarella, D., Schümann, J., Naidenko, O.V., Garavaglia, C., Beermann, F., Kronenberg, M., Dellabona, P., MacDonald, H.R. and Casorati, G. 2003. Human invariant Va24-JaQ TCR supports the development of CD1d-dependent NK1.1+ and NK1.1- T cells in transgenic mice. J. Immunol. 170:2390-2398.

Capone, M., Lees, R.K., Finke, D., Ernst, B., Van Meerwijk, J.P.M. and MacDonald, H.R. 2003. Selective absence of CD8+ TCRab+ intestinal epithelial cells in transgenic mice expressing b2-microglobulin-associated ligands exclusively on thymic cortical epithelium. Eur. J. Immunol. 33:1471-1477.

Corcoran, L., Ferrero, I., Vremec, D., Lucas, K., Waithman, J., O'Keeffe, M., Wu, L., Wilson, A. and Shortman, K. 2003. The lymphoid past of mouse plasmacytoid cells and thymic dendritic cells. J. Immunol. 170:4926-4932.

Dietrich, P.-Y., Le Gal, F.-A., Dutoit, V., Pittet, M.J., Trautmann, L., Zippelius, A., Cognet, I., Widmer, V., Walker, P.R., Michielin, O., Guillaume, P., Connerotte, T., Jotereau, F., Coulie, P.G., Romero, P., Cerottini, J.-C., Bonneville, M. and Valmori, D. 2003. Prevalent role of TCR-a chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen. J. Immunol. 170:5103-5109.

Doucey, M.-A., Goffin, L., Naeher, D., Michielin, O., Baumgärtner, P., Guillaume, P., Palmer, E. and Luescher, I.F. 2003. CD3d establishes a functional link between the T cell receptor and CD8. J. Biol. Chem. 278:3257-3264.

Doucey, M.-A., Legler, D. F., Faroudi, M., Boucheron, N., Baumgärtner, P., Naeher, D., Cebecauer, M., Hudrisier, D., Rüegg, C., Palmer, E., Valitutti, S., Bron, C. and Luescher, I.F. 2003. The b1 and b3 integrins promote T cell receptor-mediated cytotoxic T lymphocyte activation. J. Biol. Chem. 278:26983-26991.

Dutoit, V., Guillaume, P., Ayyoub, M., Hesdorffer, C. S., Luescher, I.F. and Valmori, D. 2003. Decreased binding of peptides-MHC class I (pMHC) multimeric complexes to CD8 affects their binding avidity for the TCR but does not significantly impact on pMHC/TCR dissociation rate. J. Immunol. 170:5103-5109.

Esslinger, C., Chapatte, L., Finke, D., Miconnet, I., Guillaume, P., Lévy, F. and MacDonald, H.R. 2003. In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8+ T cell responses. J. Clin. Invest. 111:1673-1681.

Finke, D., Luther, S.A. and Acha-Orbea, H. 2003. The role of neutralizing antibodies for mouse mammary tumor virus transmission and mammary cancer development. Proc. Natl. Acad. Sci. USA 100:199-204.

Guillaume, P., Legler, D.F., Boucheron, N., Doucey, M.-A., Cerottini, J.-C. and Luescher, I.F. 2003. Soluble major histocompatibility complex-peptide octamers with impaired CD8 binding selectively induce Fas-dependent apoptosis. J. Biol. Chem. 278:4500-4509.

Held, W., Clevers, H. and Grosschedl, R. 2003. Redundant functions of TCF-1 and LEF-1 during T and NK cell development, but unique role of TCF-1 for Ly49 NK cell receptor acquisition. Eur. J. Immunol. 33:1393-1398.

Held, W., Coudert, J.D. and Zimmer, J. 2003. The NK cell receptor repertoire: formation, adaptation and exploitation. Curr. Opin. Immunol. 15:233-237.

Ioannidis, V., Kunz, B., Tanamachi, D. M., Scarpellino, L. and Held, W. 2003. Initiation and limitation of Ly-49A NK cell receptor acquisition by T cell factor-1. J. Immunol. 171:769-775.

Karanikas, V., Lurquin, C., Colau, D., van Baren, N., De Smet, C., Lethé, B., Connerotte, T., Corbière, V., Demoitié, M.-A., Liénard, D., Dréno, B., Velu, T., Boon, T. and Coulie, P.G. 2003. Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J. Immunol. 171:4898-4904.

Krug, A., Rothenfusser, S., Selinger, S., Bock, C., Kerkmann, M., Battiany, J., Sarris, A., Giese, T., Speiser, D., Endres, S. and Hartmann, G. 2003. CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenothype that preferentially activates CD8 T cells. J. Immunol. 170:3468-3477.

MacDonald, H.R. 2003. Introduction: notch and lymphopoiesis. Semin. Immunol. 15:67-68.

Matter, M., Lejeune, F., Antonescu, C., Bischof Delaloye, A., Gugerli, O., Lobrinus, J. A., Cerottini, J.-P., Guggisberg, D. and Liénard, D. 2003. Revue du traitement chirurgical du mélanome malin. Med. Hyg. 2438:1088-1097.

Mpandi, M., Otten, L.A., Lavanchy, C., Acha-Orbea, H. and Finke, D. 2003. Passive immunization with neutralizing antibodies interrupts the mouse mammary tumor virus life circle. J. Virol. 77:9369-9377.

Nicolas, M., Wolfer, A., Raj, K., Kummer, A., Mill, P., van Noort, M., Hui, C.-C., Clevers, H., Dotto, G.P. and Radtke, F. 2003. Notch1 functions as a tumor suppressor in mouse skin. Nat. Genet. 33:416-421.

Otten, L.A., Tacchini-Cottier, F., Lohoff, M., Annunziato, F., Cosmi, L., Scarpellino, L., Louis, J., Steimle, V., Reith, W. and Acha-Orbea, H. 2003. Deregulated MHC class II transactivator expression leads to a strong Th2 bias in CD4+ T lymphocytes. J. Immunol. 170:1150-1157.

Pear, W. S. and Radtke, F. 2003. Notch signaling in lymphopoiesis. Semin. Immunol. 15:69-79.

Pittet, M.J., Rubio-Godoy, V., Bioley, G., Guillaume, P., Batard, P., Speiser, D., Luescher, I., Cerottini, J.-C., Romero, P. and Zippelius, A. 2003. a3-Domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cells. J. Immunol. 171:1844-1849.

Radtke, F. and Raj, K. 2003. The role of Notch in tumorigenesis: Oncogene or tumour suppressor? Nat. Rev. Cancer 3:756-767.

Ramirez, J.C., Finke, D., Esteban, M., Kraehenbuhl, J.P. and Acha-Orbea, H. 2003. Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration. Arch. Virol. 148:827-839.

Rimoldi, D., Cerottini, J.-C. and Romero, P. 2003. Fas/Fas ligand and tumor immunity. In: Mechanisms of tumor escape from the immune response. A.C. Ochoa, ed. Taylor & Francis, London and New York. pp. 213-235.

Rimoldi, D., Lemoine, R., Kurt, A.-M., Salvi, S., Berset, M., Matter, M., Roche, B., Cerottini, J.-P., Guggisberg, D., Krischer, J., Braum, R., Willi, J.-P., Antonescu, C., Slosman, D., Lejeune, F. and Liénard, D. 2003. Detection of micrometastases in sentinel lymph nodes from melanoma patients: direct comparison of multimarker molecular and immunopathological methods. Melanoma Res. 13:511-520.

Rimoldi, D., Salvi, S., Liénard, D., Lejeune, F.J., Speiser, D., Zografos, L. and Cerottini, J.-C. 2003. Lack of BRAF mutations in uveal melanoma. Cancer Res. 63:5712-5715.

Rufer, N., Zippelius, A., Batard, P., Pittet, M.J., Kurth, I., Corthesy, P., Cerottini, J.-C., Leyvraz, S., Roosnek, E., Nabholz, M. and Romero, P. 2003. Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. Blood 102:1779-1787.

Saurer, L., Seibold, I., Vallan, C., Held, W. and Mueller, C. 2003. Cutting Edge: Stimulation with the cognate self-antigen induces expression of the Ly49A receptor on self-reactive T cells which modulates their responsiveness. J. Immunol. 171: 6334-6338.

Schümann, J., Voyle, R.B., Wei, B.-Y. and MacDonald, H.R. 2003. Cutting Edge: Influence of the TCR Vb domain on the avidity of CD1d:a-galactosylceramide binding by invariant Va14 NKT cells. J. Immunol. 170:5815-5819.

Smith, J.W., Walker, E.B., Fox, B.A., Haley, D., Wisner, K.P., Doran, T., Fisher, B., Justice, L., Wood, W., Vetto, J., Maecker, H., Dols, A., Meijer, S., Hu, H.-M., Romero, P., Alvord, W.G. and Urba, W.J. 2003. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J. Clin. Oncology 21:1562-1573.

Speiser, D.E., Rimoldi, D., Batard, P., Liénard, D., Lejeune, F., Cerottini, J.-C. and Romero, P. 2003. Disease-driven T cell activation predicts immune responses to vaccination against melanoma. Cancer Immunity [serial online] 3:12.
URL: http://www.cancerimmunity.org/v3p12/030812.htm

Speiser, D.E., Pittet, M.J., Rimoldi, D., Guillaume, P., Luescher, I.F., Liénard, D., Lejeune, F., Cerottini, J.-C., and Romero, P. 2003. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells. Sem. Cancer Biol. 13:461-472.

Valmori, D., Dutoit, V., Ayyoub, M., Rimoldi, D., Guillaume, P., Liénard, D., Lejeune, F., Cerottini, J.-C., Romero, P. and Speiser, D.E. 2003. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Cancer Immunity [serial online] 3:15.
URL: http://www.cancerimmunity.org/v3p15/030915.htm

Voyle, R.B., Beermann, F., Lees, R.K., Schümann, J., Zimmer, J., Held, W. and MacDonald, H.R. 2003. Ligand-dependent inhibition of CD1d-restricted NKT cell development in mice transgenic for the activating receptor Ly49D. J. Exp. Med. 197:919-925.

Waldburger, J.-M., Rossi, S., Holländer, G.A., Rodewald, H.-R., Reith, W. and Acha-Orbea, H. 2003. Promoter IV of the Class II transactivator gene is essential for positive selection of CD4+ T cells. Blood 101:3550-3559.